Modality
Degrader
MOA
PD-1i
Target
TIGIT
Pathway
Neuroinflam
NMOSDFabry
Development Pipeline
Preclinical
~Jun 2012
→ ~Sep 2013
Phase 1
~Dec 2013
→ ~Mar 2015
Phase 2
~Jun 2015
→ ~Sep 2016
Phase 3
~Dec 2016
→ ~Mar 2018
NDA/BLA
Jun 2018
→ Apr 2027
NDA/BLACurrent
NCT03829209
658 pts·Fabry
2018-06→2027-04·Active
658 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-04-271.1y awayPh3 Readout· Fabry
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
NDA/BLA
Active
Catalysts
Ph3 Readout
2027-04-27 · 1.1y away
Fabry
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03829209 | NDA/BLA | Fabry | Active | 658 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| Miritinib | Neurocrine | Phase 3 | TIGIT | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |